Wang M, Wisniewski CA, Xiong C, Chhoy P, Goel HL, Kumar A, Zhu LJ, Li R, St. Louis PA, Ferreira LM, Pakula H, Xu Z, Loda M, Jiang Z, Brehm MA, Mercurio AM.
Science Translational Medicine (2023)
Resistance to Cancer Therapy via Upregulation of the NRP2/VEGF-C Axis Can Be Neutralized By ATYR2810
American Association for Cancer Research, 2023
Identification of Latent Transforming Growth Factor Beta Binding Protein 1 (LTBP1) as a Binding Partner of Aspartyl-tRNA Synthetase
Keystone Symposia: Fibrosis Pathogenesis and Resolution, 2023
Efzofitimod for the Treatment of Pulmonary Sarcoidosis
Culver DA, Aryal S, Barney J, Hsia CCW, James WE, Maier LA, Marts LT, Obi ON, Sporn PHS, Sweiss NJ, Shukla S, Kinnersley N, Walker G, Baughman R. CHEST (2023)
A Novel Neuropilin-2 (NRP2) Antibody for Immunohistochemical Staining of Patient Tissue Samples
European Respiratory Society, 2022
Identification of Key Extracellular Binding Proteins Implicate Role in Inflammation and Fibrosis for Alanyl- and Aspartyl-tRNA Synthetases
Keystone Symposia: Tissue Fibrosis and Repair, 2022
Efzofitimod (ATYR1923) Treatment Reduces Pro-inflammatory Serum Biomarkers in Pulmonary Sarcoidosis Patients
American Thoracic Society, 2022
Safety and Efficacy of Efzofitimod (ATYR1923), a Novel Immunomodulator for Pulmonary Sarcoidosis: Results of a Phase 1b/2a Randomized Placebo-Controlled Trial
American Thoracic Society, 2022
ATYR2810, a Fully Humanized Monoclonal Antibody Targeting the VEGF-NRP2 Pathway Sensitizes Highly Aggressive and Chemoresistant TNBC Subtypes to Chemotherapy
American Association for Cancer Research, 2022
ATYR2810 an Anti-NRP2 Monoclonal Antibody Targets Tumor Associated Macrophages
Society for Immunotherapy of Cancer, 2021